Stem definition | Drug id | CAS RN |
---|---|---|
erythropoietin type blood factors | 5157 | 209810-58-2 |
Molecule | Description |
---|---|
Synonyms:
|
acts exactly like the natural erythropoietin made by the body to stimulate red blood cell production, but it is very slightly different in its structure
|
Dose | Unit | Route |
---|---|---|
4.50 | mcg | P |
None
Date | Agency | Company | Orphan |
---|---|---|---|
Sept. 17, 2001 | FDA | AMGEN |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Death | 10098.22 | 12.86 | 5053 | 34319 | 330495 | 46316195 |
Hospitalisation | 4484.43 | 12.86 | 1761 | 37611 | 61624 | 46585066 |
Investigation | 1115.14 | 12.86 | 262 | 39110 | 1372 | 46645318 |
Haemodialysis | 972.77 | 12.86 | 345 | 39027 | 8872 | 46637818 |
Aplasia pure red cell | 894.94 | 12.86 | 271 | 39101 | 4154 | 46642536 |
Transplant | 483.32 | 12.86 | 112 | 39260 | 545 | 46646145 |
Arteriovenous fistula site complication | 462.45 | 12.86 | 103 | 39269 | 404 | 46646286 |
Dialysis | 356.53 | 12.86 | 173 | 39199 | 9943 | 46636747 |
Haemoglobin decreased | 257.50 | 12.86 | 420 | 38952 | 128529 | 46518161 |
Anaemia | 241.82 | 12.86 | 610 | 38762 | 255169 | 46391521 |
Terminal state | 228.66 | 12.86 | 82 | 39290 | 2172 | 46644518 |
Peritoneal dialysis | 210.09 | 12.86 | 51 | 39321 | 313 | 46646377 |
Renal transplant | 185.07 | 12.86 | 61 | 39311 | 1244 | 46645446 |
Renal disorder | 180.52 | 12.86 | 162 | 39210 | 26524 | 46620166 |
Drug ineffective | 176.47 | 12.86 | 188 | 39184 | 677650 | 45969040 |
Rheumatoid arthritis | 172.51 | 12.86 | 7 | 39365 | 240208 | 46406482 |
Haemoglobin abnormal | 160.91 | 12.86 | 77 | 39295 | 4286 | 46642404 |
Therapeutic response decreased | 150.88 | 12.86 | 184 | 39188 | 42961 | 46603729 |
Palliative care | 147.97 | 12.86 | 37 | 39335 | 261 | 46646429 |
Shunt occlusion | 131.73 | 12.86 | 37 | 39335 | 427 | 46646263 |
Shunt stenosis | 123.36 | 12.86 | 32 | 39340 | 266 | 46646424 |
Drug hypersensitivity | 109.02 | 12.86 | 35 | 39337 | 243790 | 46402900 |
Anti-erythropoietin antibody positive | 107.63 | 12.86 | 31 | 39341 | 394 | 46646296 |
Headache | 100.94 | 12.86 | 155 | 39217 | 478197 | 46168493 |
Arteriovenous fistula operation | 88.56 | 12.86 | 24 | 39348 | 240 | 46646450 |
Toxicity to various agents | 88.46 | 12.86 | 34 | 39338 | 211732 | 46434958 |
Transfusion | 86.84 | 12.86 | 79 | 39293 | 13152 | 46633538 |
Haemoglobin increased | 83.39 | 12.86 | 42 | 39330 | 2613 | 46644077 |
Renal impairment | 82.40 | 12.86 | 189 | 39183 | 74183 | 46572507 |
Myelodysplastic syndrome | 80.78 | 12.86 | 82 | 39290 | 15629 | 46631061 |
Renal failure | 78.33 | 12.86 | 242 | 39130 | 113352 | 46533338 |
Condition aggravated | 72.73 | 12.86 | 60 | 39312 | 244992 | 46401698 |
Mineral supplementation | 69.65 | 12.86 | 24 | 39348 | 563 | 46646127 |
Peritonitis | 67.02 | 12.86 | 85 | 39287 | 20629 | 46626061 |
Arthralgia | 65.97 | 12.86 | 130 | 39242 | 364473 | 46282217 |
Drug intolerance | 60.72 | 12.86 | 24 | 39348 | 147025 | 46499665 |
Rehabilitation therapy | 59.59 | 12.86 | 26 | 39346 | 1166 | 46645524 |
Psoriasis | 54.05 | 12.86 | 3 | 39369 | 78601 | 46568089 |
Joint swelling | 53.94 | 12.86 | 37 | 39335 | 166036 | 46480654 |
Unevaluable event | 52.96 | 12.86 | 119 | 39253 | 46056 | 46600634 |
Sinusitis | 52.24 | 12.86 | 22 | 39350 | 129746 | 46516944 |
Hip fracture | 52.16 | 12.86 | 86 | 39286 | 26470 | 46620220 |
Nephrogenic systemic fibrosis | 51.36 | 12.86 | 38 | 39334 | 4734 | 46641956 |
Product use issue | 51.24 | 12.86 | 9 | 39363 | 94635 | 46552055 |
Azotaemia | 47.62 | 12.86 | 35 | 39337 | 4316 | 46642374 |
Refractory cytopenia with unilineage dysplasia | 47.18 | 12.86 | 18 | 39354 | 569 | 46646121 |
Infusion related reaction | 46.11 | 12.86 | 14 | 39358 | 101194 | 46545496 |
Pain | 45.76 | 12.86 | 227 | 39145 | 476721 | 46169969 |
Weight increased | 45.46 | 12.86 | 43 | 39329 | 164430 | 46482260 |
Drug interaction | 45.42 | 12.86 | 63 | 39309 | 203031 | 46443659 |
Injection site erythema | 45.16 | 12.86 | 5 | 39367 | 74422 | 46572268 |
Cardiac failure | 44.94 | 12.86 | 159 | 39213 | 79789 | 46566901 |
Nausea | 42.80 | 12.86 | 373 | 38999 | 687081 | 45959609 |
Cardiac output decreased | 42.71 | 12.86 | 19 | 39353 | 893 | 46645797 |
Somnolence | 42.01 | 12.86 | 42 | 39330 | 156479 | 46490211 |
Reticulocyte count decreased | 41.65 | 12.86 | 15 | 39357 | 402 | 46646288 |
Anti-erythropoietin antibody negative | 40.31 | 12.86 | 10 | 39362 | 68 | 46646622 |
Transformation to acute myeloid leukaemia | 39.72 | 12.86 | 11 | 39361 | 120 | 46646570 |
Living in residential institution | 38.88 | 12.86 | 14 | 39358 | 375 | 46646315 |
Arteriovenous fistula site infection | 38.30 | 12.86 | 9 | 39363 | 47 | 46646643 |
Drug specific antibody absent | 37.53 | 12.86 | 9 | 39363 | 52 | 46646638 |
Haemodialysis complication | 35.98 | 12.86 | 12 | 39360 | 254 | 46646436 |
Depression | 35.83 | 12.86 | 55 | 39317 | 170049 | 46476641 |
Hepatic cyst infection | 35.32 | 12.86 | 10 | 39362 | 119 | 46646571 |
End stage renal disease | 34.49 | 12.86 | 33 | 39339 | 5853 | 46640837 |
Dizziness | 33.75 | 12.86 | 160 | 39212 | 340254 | 46306436 |
Alopecia | 33.74 | 12.86 | 53 | 39319 | 162361 | 46484329 |
Reticulocyte count abnormal | 32.56 | 12.86 | 8 | 39364 | 52 | 46646638 |
Blood parathyroid hormone increased | 32.48 | 12.86 | 24 | 39348 | 2984 | 46643706 |
Renal cyst infection | 32.43 | 12.86 | 9 | 39363 | 99 | 46646591 |
Off label use | 31.98 | 12.86 | 473 | 38899 | 379368 | 46267322 |
Arthropathy | 31.53 | 12.86 | 16 | 39356 | 84684 | 46562006 |
Disease progression | 31.23 | 12.86 | 156 | 39216 | 91144 | 46555546 |
Treatment failure | 31.20 | 12.86 | 20 | 39352 | 93067 | 46553623 |
Thrombocytopenia | 31.18 | 12.86 | 198 | 39174 | 126383 | 46520307 |
Hepatic enzyme increased | 31.13 | 12.86 | 15 | 39357 | 81772 | 46564918 |
Abdominal discomfort | 30.76 | 12.86 | 50 | 39322 | 151115 | 46495575 |
Nasopharyngitis | 30.35 | 12.86 | 52 | 39320 | 153946 | 46492744 |
Musculoskeletal stiffness | 30.27 | 12.86 | 23 | 39349 | 97970 | 46548720 |
Therapeutic product effect incomplete | 30.25 | 12.86 | 14 | 39358 | 78139 | 46568551 |
Cardiac disorder | 29.78 | 12.86 | 93 | 39279 | 43765 | 46602925 |
Pleural effusion | 29.27 | 12.86 | 143 | 39229 | 82809 | 46563881 |
Chronic kidney disease | 28.99 | 12.86 | 88 | 39284 | 40783 | 46605907 |
Shunt infection | 28.69 | 12.86 | 7 | 39365 | 44 | 46646646 |
Anti-erythropoietin antibody | 28.05 | 12.86 | 5 | 39367 | 3 | 46646687 |
Product dose omission issue | 27.14 | 12.86 | 64 | 39308 | 168456 | 46478234 |
Iron deficiency | 26.51 | 12.86 | 28 | 39344 | 5585 | 46641105 |
Lower respiratory tract infection | 26.31 | 12.86 | 104 | 39268 | 54985 | 46591705 |
Occupational exposure to product | 26.29 | 12.86 | 17 | 39355 | 1704 | 46644986 |
Serum ferritin increased | 26.11 | 12.86 | 27 | 39345 | 5256 | 46641434 |
Neoplasm malignant | 25.20 | 12.86 | 59 | 39313 | 23440 | 46623250 |
Asthma | 25.20 | 12.86 | 24 | 39348 | 91518 | 46555172 |
Migraine | 24.93 | 12.86 | 14 | 39358 | 70012 | 46576678 |
Pain in extremity | 24.79 | 12.86 | 123 | 39249 | 258557 | 46388133 |
Fungal endocarditis | 24.69 | 12.86 | 9 | 39363 | 250 | 46646440 |
Peripheral swelling | 24.69 | 12.86 | 61 | 39311 | 158010 | 46488680 |
Home care | 24.32 | 12.86 | 4 | 39368 | 0 | 46646690 |
Leukopenia | 24.23 | 12.86 | 118 | 39254 | 68225 | 46578465 |
Visual impairment | 24.22 | 12.86 | 13 | 39359 | 66676 | 46580014 |
Memory impairment | 24.08 | 12.86 | 18 | 39354 | 77319 | 46569371 |
Diabetic complication | 23.69 | 12.86 | 13 | 39359 | 964 | 46645726 |
Swelling | 23.66 | 12.86 | 43 | 39329 | 124468 | 46522222 |
Overdose | 23.41 | 12.86 | 31 | 39341 | 101948 | 46544742 |
Injection site pruritus | 23.29 | 12.86 | 3 | 39369 | 39740 | 46606950 |
Transplant failure | 23.22 | 12.86 | 14 | 39358 | 1240 | 46645450 |
Injection site reaction | 22.93 | 12.86 | 6 | 39366 | 47843 | 46598847 |
Eye infection bacterial | 22.93 | 12.86 | 7 | 39365 | 110 | 46646580 |
Arthritis | 22.80 | 12.86 | 19 | 39353 | 77297 | 46569393 |
Intentional product use issue | 22.80 | 12.86 | 8 | 39364 | 52772 | 46593918 |
Pancytopenia | 22.79 | 12.86 | 136 | 39236 | 84922 | 46561768 |
Fluid overload | 22.63 | 12.86 | 62 | 39310 | 27123 | 46619567 |
Fall | 22.48 | 12.86 | 396 | 38976 | 328701 | 46317989 |
Arteriovenous fistula thrombosis | 22.37 | 12.86 | 8 | 39364 | 210 | 46646480 |
Anxiety | 22.07 | 12.86 | 79 | 39293 | 181878 | 46464812 |
Skin induration | 21.99 | 12.86 | 19 | 39353 | 2955 | 46643735 |
Hypertension | 21.66 | 12.86 | 257 | 39115 | 196099 | 46450591 |
Insomnia | 21.09 | 12.86 | 70 | 39302 | 164854 | 46481836 |
Systemic lupus erythematosus | 20.51 | 12.86 | 15 | 39357 | 65165 | 46581525 |
Parakeratosis | 20.40 | 12.86 | 7 | 39365 | 162 | 46646528 |
Product use in unapproved indication | 20.15 | 12.86 | 28 | 39344 | 90245 | 46556445 |
Infective aneurysm | 20.11 | 12.86 | 9 | 39363 | 429 | 46646261 |
Nephrogenic anaemia | 20.06 | 12.86 | 15 | 39357 | 1898 | 46644792 |
Exposure during pregnancy | 20.00 | 12.86 | 38 | 39334 | 108174 | 46538516 |
Agitation | 19.84 | 12.86 | 11 | 39361 | 55404 | 46591286 |
Myelodysplastic syndrome transformation | 19.67 | 12.86 | 9 | 39363 | 452 | 46646238 |
Nasal congestion | 19.60 | 12.86 | 8 | 39364 | 48105 | 46598585 |
Marasmus | 19.34 | 12.86 | 9 | 39363 | 470 | 46646220 |
Bone marrow failure | 19.30 | 12.86 | 62 | 39310 | 29607 | 46617083 |
Blood cholesterol increased | 19.21 | 12.86 | 5 | 39367 | 40008 | 46606682 |
Hyperphosphataemia | 19.15 | 12.86 | 14 | 39358 | 1712 | 46644978 |
Urinary tract infection | 19.15 | 12.86 | 276 | 39096 | 219990 | 46426700 |
Therapeutic product effect decreased | 19.07 | 12.86 | 25 | 39347 | 82576 | 46564114 |
Blood erythropoietin increased | 19.04 | 12.86 | 4 | 39368 | 11 | 46646679 |
Extramedullary haemopoiesis | 18.92 | 12.86 | 5 | 39367 | 45 | 46646645 |
Sleep disorder | 18.71 | 12.86 | 8 | 39364 | 46787 | 46599903 |
Kidney transplant rejection | 18.49 | 12.86 | 20 | 39352 | 4098 | 46642592 |
Gait disturbance | 18.33 | 12.86 | 62 | 39310 | 145201 | 46501489 |
Abortion spontaneous | 18.20 | 12.86 | 7 | 39365 | 43639 | 46603051 |
Myalgia | 18.06 | 12.86 | 49 | 39323 | 123039 | 46523651 |
Rash | 18.05 | 12.86 | 203 | 39169 | 356309 | 46290381 |
Product quality issue | 18.00 | 12.86 | 4 | 39368 | 35644 | 46611046 |
Blood creatinine increased | 17.87 | 12.86 | 118 | 39254 | 76285 | 46570405 |
Product storage error | 17.75 | 12.86 | 34 | 39338 | 11758 | 46634932 |
Sepsis | 17.72 | 12.86 | 184 | 39188 | 135830 | 46510860 |
Blood test abnormal | 17.58 | 12.86 | 30 | 39342 | 9490 | 46637200 |
Cough | 17.48 | 12.86 | 118 | 39254 | 230131 | 46416559 |
Angina pectoris | 17.46 | 12.86 | 56 | 39316 | 26719 | 46619971 |
Chronic kidney disease-mineral and bone disorder | 17.21 | 12.86 | 7 | 39365 | 263 | 46646427 |
Hypersensitivity | 17.09 | 12.86 | 67 | 39305 | 150254 | 46496436 |
Urine odour abnormal | 17.06 | 12.86 | 21 | 39351 | 4941 | 46641749 |
Hypervolaemia | 16.95 | 12.86 | 13 | 39359 | 1709 | 46644981 |
Pneumonia | 16.93 | 12.86 | 426 | 38946 | 375894 | 46270796 |
Haemolysis | 16.71 | 12.86 | 23 | 39349 | 6036 | 46640654 |
Blood product transfusion dependent | 16.65 | 12.86 | 6 | 39366 | 161 | 46646529 |
Amegakaryocytic thrombocytopenia | 16.55 | 12.86 | 4 | 39368 | 24 | 46646666 |
Natural killer cell count | 16.55 | 12.86 | 4 | 39368 | 24 | 46646666 |
Wrong technique in product usage process | 16.51 | 12.86 | 13 | 39359 | 54409 | 46592281 |
Dialysis related complication | 16.41 | 12.86 | 5 | 39367 | 78 | 46646612 |
Renovascular hypertension | 16.16 | 12.86 | 3 | 39369 | 3 | 46646687 |
Dry eye | 16.15 | 12.86 | 3 | 39369 | 30319 | 46616371 |
Macrophages increased | 16.15 | 12.86 | 4 | 39368 | 27 | 46646663 |
Cellulitis | 16.10 | 12.86 | 108 | 39264 | 70180 | 46576510 |
Arteriovenous fistula occlusion | 15.87 | 12.86 | 7 | 39365 | 322 | 46646368 |
Maternal condition affecting foetus | 15.75 | 12.86 | 6 | 39366 | 189 | 46646501 |
Glossodynia | 15.61 | 12.86 | 9 | 39363 | 44364 | 46602326 |
Hyperparathyroidism secondary | 15.60 | 12.86 | 11 | 39361 | 1271 | 46645419 |
Skin hypertrophy | 15.55 | 12.86 | 16 | 39356 | 3095 | 46643595 |
Blood potassium increased | 15.44 | 12.86 | 40 | 39332 | 16927 | 46629763 |
Arteriovenous fistula site haemorrhage | 15.31 | 12.86 | 6 | 39366 | 204 | 46646486 |
Osteoarthritis | 15.12 | 12.86 | 18 | 39354 | 62007 | 46584683 |
Leg amputation | 14.89 | 12.86 | 13 | 39359 | 2050 | 46644640 |
Epistaxis | 14.84 | 12.86 | 99 | 39273 | 64206 | 46582484 |
Alanine aminotransferase increased | 14.70 | 12.86 | 33 | 39339 | 88418 | 46558272 |
Shunt thrombosis | 14.67 | 12.86 | 4 | 39368 | 41 | 46646649 |
Vascular shunt | 14.63 | 12.86 | 3 | 39369 | 7 | 46646683 |
Medication error | 14.58 | 12.86 | 4 | 39368 | 30907 | 46615783 |
Anaphylactic reaction | 14.52 | 12.86 | 14 | 39358 | 53098 | 46593592 |
Plasma cell myeloma | 14.49 | 12.86 | 75 | 39297 | 44403 | 46602287 |
Flushing | 14.46 | 12.86 | 20 | 39352 | 64594 | 46582096 |
Intermittent claudication | 14.21 | 12.86 | 12 | 39360 | 1808 | 46644882 |
Upper respiratory tract infection | 13.90 | 12.86 | 20 | 39352 | 63536 | 46583154 |
Renal transplant failure | 13.89 | 12.86 | 8 | 39364 | 651 | 46646039 |
Hepatitis | 13.71 | 12.86 | 5 | 39367 | 32210 | 46614480 |
Skin ulcer | 13.70 | 12.86 | 59 | 39313 | 32399 | 46614291 |
Skin fibrosis | 13.62 | 12.86 | 9 | 39363 | 936 | 46645754 |
Loss of personal independence in daily activities | 13.51 | 12.86 | 17 | 39355 | 57166 | 46589524 |
Pulmonary arterial hypertension | 12.91 | 12.86 | 3 | 39369 | 25925 | 46620765 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Death | 12374.60 | 13.69 | 6931 | 34658 | 350352 | 29560537 |
Hospitalisation | 5084.15 | 13.69 | 2004 | 39585 | 42315 | 29868574 |
Aplasia pure red cell | 1160.38 | 13.69 | 394 | 41195 | 5232 | 29905657 |
Haemodialysis | 1016.46 | 13.69 | 429 | 41160 | 10644 | 29900245 |
Investigation | 885.84 | 13.69 | 214 | 41375 | 697 | 29910192 |
Arteriovenous fistula site complication | 716.53 | 13.69 | 157 | 41432 | 279 | 29910610 |
Transplant | 443.17 | 13.69 | 115 | 41474 | 537 | 29910352 |
Dialysis | 377.37 | 13.69 | 218 | 41371 | 10778 | 29900111 |
Peritoneal dialysis | 264.35 | 13.69 | 73 | 41516 | 450 | 29910439 |
Haemoglobin abnormal | 246.72 | 13.69 | 109 | 41480 | 3020 | 29907869 |
Haemoglobin decreased | 227.59 | 13.69 | 494 | 41095 | 113604 | 29797285 |
Anti-erythropoietin antibody positive | 193.65 | 13.69 | 65 | 41524 | 828 | 29910061 |
Therapeutic response decreased | 184.34 | 13.69 | 197 | 41392 | 24152 | 29886737 |
Renal disorder | 171.85 | 13.69 | 187 | 41402 | 23397 | 29887492 |
Terminal state | 158.01 | 13.69 | 84 | 41505 | 3520 | 29907369 |
Anaemia | 144.58 | 13.69 | 621 | 40968 | 207371 | 29703518 |
Transfusion | 139.46 | 13.69 | 101 | 41488 | 7360 | 29903529 |
Palliative care | 123.49 | 13.69 | 37 | 41552 | 316 | 29910573 |
Toxicity to various agents | 118.42 | 13.69 | 49 | 41540 | 177134 | 29733755 |
Shunt stenosis | 112.72 | 13.69 | 35 | 41554 | 341 | 29910548 |
Renal transplant | 105.66 | 13.69 | 51 | 41538 | 1737 | 29909152 |
Arteriovenous fistula operation | 101.37 | 13.69 | 27 | 41562 | 142 | 29910747 |
Reticulocyte count decreased | 91.08 | 13.69 | 33 | 41556 | 534 | 29910355 |
Myelodysplastic syndrome | 89.37 | 13.69 | 120 | 41469 | 18658 | 29892231 |
Haemoglobin increased | 85.05 | 13.69 | 52 | 41537 | 2850 | 29908039 |
Drug interaction | 80.80 | 13.69 | 95 | 41494 | 199473 | 29711416 |
Lower respiratory tract infection | 74.04 | 13.69 | 133 | 41456 | 26581 | 29884308 |
Shunt occlusion | 69.59 | 13.69 | 28 | 41561 | 610 | 29910279 |
Neoplasm malignant | 68.74 | 13.69 | 103 | 41486 | 17711 | 29893178 |
Living in residential institution | 68.43 | 13.69 | 21 | 41568 | 196 | 29910693 |
Hip fracture | 65.43 | 13.69 | 79 | 41510 | 11045 | 29899844 |
Mineral supplementation | 61.94 | 13.69 | 16 | 41573 | 73 | 29910816 |
Headache | 59.61 | 13.69 | 101 | 41488 | 182205 | 29728684 |
Drug ineffective | 57.79 | 13.69 | 260 | 41329 | 340127 | 29570762 |
Product use in unapproved indication | 56.72 | 13.69 | 16 | 41573 | 73677 | 29837212 |
Transformation to acute myeloid leukaemia | 55.79 | 13.69 | 24 | 41565 | 622 | 29910267 |
Nephrogenic systemic fibrosis | 55.30 | 13.69 | 47 | 41542 | 4324 | 29906565 |
Azotaemia | 52.17 | 13.69 | 48 | 41541 | 4904 | 29905985 |
Overdose | 52.07 | 13.69 | 26 | 41563 | 84311 | 29826578 |
Chronic kidney disease | 48.87 | 13.69 | 139 | 41450 | 37699 | 29873190 |
Arteriovenous fistula site infection | 48.87 | 13.69 | 13 | 41576 | 68 | 29910821 |
Arteriovenous fistula thrombosis | 48.01 | 13.69 | 18 | 41571 | 322 | 29910567 |
Peritonitis | 46.43 | 13.69 | 96 | 41493 | 21279 | 29889610 |
Product use issue | 46.20 | 13.69 | 5 | 41584 | 46011 | 29864878 |
Appendicolith | 44.79 | 13.69 | 23 | 41566 | 896 | 29909993 |
Rehabilitation therapy | 44.31 | 13.69 | 20 | 41569 | 583 | 29910306 |
Alanine aminotransferase increased | 42.78 | 13.69 | 25 | 41564 | 74251 | 29836638 |
Unevaluable event | 42.25 | 13.69 | 118 | 41471 | 31667 | 29879222 |
Product storage error | 41.92 | 13.69 | 48 | 41541 | 6343 | 29904546 |
Angina pectoris | 41.64 | 13.69 | 112 | 41477 | 29406 | 29881483 |
Somnolence | 40.23 | 13.69 | 45 | 41544 | 96718 | 29814171 |
Aggression | 39.76 | 13.69 | 3 | 41586 | 36904 | 29873985 |
Suicidal ideation | 38.72 | 13.69 | 3 | 41586 | 36111 | 29874778 |
Refractory cytopenia with unilineage dysplasia | 38.60 | 13.69 | 17 | 41572 | 467 | 29910422 |
Nausea | 37.05 | 13.69 | 251 | 41338 | 296706 | 29614183 |
Zoonotic bacterial infection | 36.58 | 13.69 | 10 | 41579 | 59 | 29910830 |
Depression | 35.51 | 13.69 | 44 | 41545 | 90393 | 29820496 |
Hyperhidrosis | 35.33 | 13.69 | 25 | 41564 | 67065 | 29843824 |
Intermittent claudication | 34.53 | 13.69 | 27 | 41562 | 2207 | 29908682 |
Product dose omission issue | 34.51 | 13.69 | 46 | 41543 | 91585 | 29819304 |
Hallucination | 33.62 | 13.69 | 13 | 41576 | 49046 | 29861843 |
Rheumatoid arthritis | 33.49 | 13.69 | 8 | 41581 | 41189 | 29869700 |
Home care | 33.49 | 13.69 | 6 | 41583 | 0 | 29910889 |
Normochromic normocytic anaemia | 33.38 | 13.69 | 34 | 41555 | 3936 | 29906953 |
Aspartate aminotransferase increased | 32.91 | 13.69 | 24 | 41565 | 63398 | 29847491 |
Leg amputation | 32.73 | 13.69 | 26 | 41563 | 2175 | 29908714 |
Fluid overload | 32.72 | 13.69 | 78 | 41511 | 19014 | 29891875 |
Dizziness | 32.29 | 13.69 | 150 | 41439 | 194759 | 29716130 |
Hepatic cyst infection | 32.09 | 13.69 | 7 | 41582 | 12 | 29910877 |
Urinary tract infection | 31.93 | 13.69 | 193 | 41396 | 73466 | 29837423 |
Arthralgia | 30.64 | 13.69 | 92 | 41497 | 135699 | 29775190 |
Myalgia | 30.41 | 13.69 | 37 | 41552 | 76630 | 29834259 |
Mycobacterium marinum infection | 30.41 | 13.69 | 12 | 41577 | 248 | 29910641 |
Erythropoiesis abnormal | 29.91 | 13.69 | 11 | 41578 | 186 | 29910703 |
Weight increased | 29.88 | 13.69 | 36 | 41553 | 74877 | 29836012 |
Intentional product use issue | 29.77 | 13.69 | 7 | 41582 | 36433 | 29874456 |
Angiodysplasia | 29.46 | 13.69 | 14 | 41575 | 460 | 29910429 |
Tachycardia | 28.81 | 13.69 | 36 | 41553 | 73703 | 29837186 |
Agitation | 28.66 | 13.69 | 20 | 41569 | 54053 | 29856836 |
Interstitial lung disease | 28.45 | 13.69 | 25 | 41564 | 60172 | 29850717 |
Drug hypersensitivity | 28.32 | 13.69 | 32 | 41557 | 68487 | 29842402 |
Reticulocytopenia | 28.22 | 13.69 | 8 | 41581 | 55 | 29910834 |
Joint swelling | 28.18 | 13.69 | 15 | 41574 | 46931 | 29863958 |
Condition aggravated | 27.92 | 13.69 | 98 | 41491 | 137768 | 29773121 |
Infusion related reaction | 27.38 | 13.69 | 11 | 41578 | 40553 | 29870336 |
Tremor | 26.23 | 13.69 | 40 | 41549 | 75323 | 29835566 |
Rhabdomyolysis | 25.94 | 13.69 | 30 | 41559 | 63550 | 29847339 |
Treatment failure | 25.81 | 13.69 | 8 | 41581 | 34671 | 29876218 |
Catheter removal | 25.74 | 13.69 | 10 | 41579 | 198 | 29910691 |
Lactic acidosis | 25.49 | 13.69 | 6 | 41583 | 31207 | 29879682 |
Cardio-respiratory arrest | 24.52 | 13.69 | 26 | 41563 | 57280 | 29853609 |
Hepatic enzyme increased | 24.44 | 13.69 | 8 | 41581 | 33486 | 29877403 |
Sinusitis | 24.27 | 13.69 | 8 | 41581 | 33337 | 29877552 |
Transferrin saturation increased | 23.88 | 13.69 | 7 | 41582 | 55 | 29910834 |
Blood iron abnormal | 23.76 | 13.69 | 7 | 41582 | 56 | 29910833 |
End stage renal disease | 23.17 | 13.69 | 39 | 41550 | 7396 | 29903493 |
Gangrene | 22.73 | 13.69 | 30 | 41559 | 4584 | 29906305 |
Chest discomfort | 22.58 | 13.69 | 18 | 41571 | 45462 | 29865427 |
Anti-erythropoietin antibody | 22.32 | 13.69 | 4 | 41585 | 0 | 29910889 |
Blood creatine phosphokinase increased | 22.22 | 13.69 | 17 | 41572 | 43831 | 29867058 |
Irritability | 21.91 | 13.69 | 3 | 41586 | 23047 | 29887842 |
Anxiety | 21.64 | 13.69 | 59 | 41530 | 89812 | 29821077 |
Pleural effusion | 21.47 | 13.69 | 176 | 41413 | 73890 | 29836999 |
Catheter placement | 21.27 | 13.69 | 13 | 41576 | 712 | 29910177 |
Non-neutralising antibodies positive | 20.93 | 13.69 | 7 | 41582 | 88 | 29910801 |
Pyrexia | 20.84 | 13.69 | 286 | 41303 | 294203 | 29616686 |
Angioedema | 20.61 | 13.69 | 11 | 41578 | 34373 | 29876516 |
Renal cyst infection | 19.95 | 13.69 | 6 | 41583 | 52 | 29910837 |
Insomnia | 19.80 | 13.69 | 65 | 41524 | 93271 | 29817618 |
Hyperparathyroidism secondary | 19.74 | 13.69 | 15 | 41574 | 1175 | 29909714 |
Drug-induced liver injury | 19.69 | 13.69 | 3 | 41586 | 21271 | 29889618 |
Asthma | 19.67 | 13.69 | 13 | 41576 | 36161 | 29874728 |
Respiratory failure | 19.39 | 13.69 | 73 | 41516 | 100569 | 29810320 |
Parvovirus B19 test positive | 19.28 | 13.69 | 7 | 41582 | 114 | 29910775 |
Renal transplant failure | 19.12 | 13.69 | 14 | 41575 | 1037 | 29909852 |
Foetal exposure during pregnancy | 19.06 | 13.69 | 14 | 41575 | 36857 | 29874032 |
Iron overload | 18.76 | 13.69 | 15 | 41574 | 1266 | 29909623 |
Coronary artery disease | 18.66 | 13.69 | 25 | 41564 | 49687 | 29861202 |
Skin induration | 18.65 | 13.69 | 19 | 41570 | 2200 | 29908689 |
Skin fibrosis | 18.63 | 13.69 | 14 | 41575 | 1079 | 29909810 |
Psoriasis | 18.50 | 13.69 | 19 | 41570 | 42487 | 29868402 |
Cognitive disorder | 18.48 | 13.69 | 5 | 41584 | 23685 | 29887204 |
Acute respiratory distress syndrome | 18.23 | 13.69 | 5 | 41584 | 23467 | 29887422 |
Electrocardiogram QT prolonged | 18.02 | 13.69 | 14 | 41575 | 35821 | 29875068 |
Arteriovenous fistula occlusion | 17.77 | 13.69 | 7 | 41582 | 144 | 29910745 |
Blood product transfusion dependent | 17.73 | 13.69 | 9 | 41580 | 342 | 29910547 |
Muscle spasms | 17.61 | 13.69 | 40 | 41549 | 64798 | 29846091 |
Cardiac valve disease | 17.43 | 13.69 | 21 | 41568 | 2928 | 29907961 |
Bradycardia | 17.33 | 13.69 | 41 | 41548 | 65485 | 29845404 |
Reticulocyte count abnormal | 17.33 | 13.69 | 4 | 41585 | 10 | 29910879 |
Acute kidney injury | 17.26 | 13.69 | 272 | 41317 | 273570 | 29637319 |
Abnormal behaviour | 17.21 | 13.69 | 7 | 41582 | 25616 | 29885273 |
Benign neoplasm | 17.09 | 13.69 | 7 | 41582 | 160 | 29910729 |
Fall | 16.89 | 13.69 | 350 | 41239 | 181522 | 29729367 |
Oedema due to renal disease | 16.74 | 13.69 | 3 | 41586 | 0 | 29910889 |
Depressed level of consciousness | 16.73 | 13.69 | 17 | 41572 | 38205 | 29872684 |
Toe amputation | 16.71 | 13.69 | 18 | 41571 | 2223 | 29908666 |
Disturbance in attention | 16.66 | 13.69 | 5 | 41584 | 22124 | 29888765 |
Abdominal pain upper | 16.65 | 13.69 | 39 | 41550 | 62512 | 29848377 |
Heart valve operation | 16.55 | 13.69 | 5 | 41584 | 44 | 29910845 |
Metastatic neoplasm | 16.51 | 13.69 | 20 | 41569 | 2805 | 29908084 |
Blood bilirubin increased | 16.38 | 13.69 | 16 | 41573 | 36620 | 29874269 |
Skin tightness | 16.36 | 13.69 | 17 | 41572 | 2015 | 29908874 |
Rash | 16.33 | 13.69 | 179 | 41410 | 191710 | 29719179 |
Oxygen saturation decreased | 16.15 | 13.69 | 22 | 41567 | 43418 | 29867471 |
Sleep disorder | 15.94 | 13.69 | 7 | 41582 | 24472 | 29886417 |
Inadequate osteointegration | 15.91 | 13.69 | 4 | 41585 | 16 | 29910873 |
Pain in extremity | 15.85 | 13.69 | 89 | 41500 | 110132 | 29800757 |
Memory impairment | 15.75 | 13.69 | 17 | 41572 | 37157 | 29873732 |
Vision blurred | 15.72 | 13.69 | 21 | 41568 | 41795 | 29869094 |
Delirium | 15.69 | 13.69 | 20 | 41569 | 40611 | 29870278 |
Kidney infection | 15.60 | 13.69 | 25 | 41564 | 4553 | 29906336 |
Serotonin syndrome | 15.51 | 13.69 | 3 | 41586 | 17888 | 29893001 |
Fracture | 15.49 | 13.69 | 29 | 41560 | 5977 | 29904912 |
Surgery | 15.45 | 13.69 | 43 | 41546 | 11508 | 29899381 |
Weight decreased | 15.26 | 13.69 | 135 | 41454 | 150786 | 29760103 |
Arteriovenous fistula site haemorrhage | 15.25 | 13.69 | 6 | 41583 | 123 | 29910766 |
Visual impairment | 15.17 | 13.69 | 12 | 41577 | 30426 | 29880463 |
Skin hypertrophy | 14.93 | 13.69 | 18 | 41571 | 2511 | 29908378 |
Hyperphosphataemia | 14.87 | 13.69 | 17 | 41572 | 2242 | 29908647 |
Hepatic function abnormal | 14.84 | 13.69 | 22 | 41567 | 41923 | 29868966 |
Cardiac failure | 14.79 | 13.69 | 179 | 41410 | 83239 | 29827650 |
Dysgeusia | 14.77 | 13.69 | 8 | 41581 | 24793 | 29886096 |
Gallbladder disorder | 14.72 | 13.69 | 28 | 41561 | 5839 | 29905050 |
Arteriovenous graft thrombosis | 14.67 | 13.69 | 3 | 41586 | 3 | 29910886 |
Dyskinesia | 14.60 | 13.69 | 6 | 41583 | 21828 | 29889061 |
Musculoskeletal stiffness | 14.56 | 13.69 | 17 | 41572 | 35864 | 29875025 |
Depressed mood | 14.46 | 13.69 | 3 | 41586 | 17026 | 29893863 |
Pneumonia | 14.23 | 13.69 | 583 | 41006 | 333723 | 29577166 |
Dry mouth | 14.16 | 13.69 | 7 | 41582 | 22843 | 29888046 |
Haematochezia | 14.11 | 13.69 | 16 | 41573 | 34206 | 29876683 |
Dental restoration failure | 14.05 | 13.69 | 4 | 41585 | 28 | 29910861 |
Dialysis device insertion | 13.92 | 13.69 | 4 | 41585 | 29 | 29910860 |
Inappropriate schedule of product administration | 13.90 | 13.69 | 21 | 41568 | 39707 | 29871182 |
Social problem | 13.86 | 13.69 | 10 | 41579 | 724 | 29910165 |
Hepatotoxicity | 13.84 | 13.69 | 4 | 41585 | 18141 | 29892748 |
Serum ferritin increased | 13.71 | 13.69 | 26 | 41563 | 5411 | 29905478 |
Source | Code | Description |
---|---|---|
ATC | B03XA02 | BLOOD AND BLOOD FORMING ORGANS ANTIANEMIC PREPARATIONS OTHER ANTIANEMIC PREPARATIONS Other antianemic preparations |
FDA CS | M0007726 | Erythropoietin |
FDA PE | N0000009319 | Increased Erythroid Cell Production |
FDA EPC | N0000175665 | Erythropoiesis-stimulating Agent |
MeSH PA | D006397 | Hematinics |
MeSH PA | D006401 | Hematologic Agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Anemia of renal disease | indication | 234348004 | |
Anemia due to and following chemotherapy | indication | 767657005 | |
Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
None
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Erythropoietin receptor | Membrane receptor | AGONIST | DRUG LABEL | DRUG LABEL |
ID | Source |
---|---|
4021274 | VANDF |
C0937950 | UMLSCUI |
CHEMBL1201566 | ChEMBL_ID |
DB00012 | DRUGBANK_ID |
D000068256 | MESH_DESCRIPTOR_UI |
D03651 | KEGG_DRUG |
8073 | INN_ID |
15UQ94PT4P | UNII |
283838 | RXNORM |
16174 | MMSL |
235606 | MMSL |
42263 | MMSL |
d04771 | MMSL |
009195 | NDDF |
385608005 | SNOMEDCT_US |
385610007 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
ARANESP | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55513-002 | SOLUTION | 25 ug | INTRAVENOUS | BLA | 29 sections |
ARANESP | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55513-003 | SOLUTION | 40 ug | INTRAVENOUS | BLA | 29 sections |
ARANESP | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55513-004 | SOLUTION | 60 ug | INTRAVENOUS | BLA | 29 sections |
ARANESP | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55513-005 | SOLUTION | 100 ug | INTRAVENOUS | BLA | 29 sections |
ARANESP | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55513-006 | SOLUTION | 200 ug | INTRAVENOUS | BLA | 29 sections |
ARANESP | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55513-021 | INJECTION, SOLUTION | 40 ug | INTRAVENOUS | BLA | 29 sections |
ARANESP | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55513-023 | INJECTION, SOLUTION | 60 ug | INTRAVENOUS | BLA | 29 sections |
ARANESP | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55513-025 | INJECTION, SOLUTION | 100 ug | INTRAVENOUS | BLA | 29 sections |
ARANESP | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55513-027 | INJECTION, SOLUTION | 150 ug | INTRAVENOUS | BLA | 29 sections |
ARANESP | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55513-028 | INJECTION, SOLUTION | 200 ug | INTRAVENOUS | BLA | 29 sections |
ARANESP | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55513-032 | INJECTION, SOLUTION | 500 ug | INTRAVENOUS | BLA | 29 sections |
ARANESP | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55513-057 | INJECTION, SOLUTION | 25 ug | INTRAVENOUS | BLA | 29 sections |
ARANESP | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55513-098 | INJECTION, SOLUTION | 10 ug | INTRAVENOUS | BLA | 29 sections |
ARANESP | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55513-110 | SOLUTION | 300 ug | INTRAVENOUS | BLA | 29 sections |
ARANESP | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55513-111 | INJECTION, SOLUTION | 300 ug | INTRAVENOUS | BLA | 29 sections |